General Atlantic

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

9 Jan 2025

Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

Verdiva Bio develops next-generation obesity and metabolic disease therapies, advancing oral and injectable treatment candidates to improve access, adherence and long-term outcomes.

General Atlantic

- Life Sciences
generalatlantic.com
Update Information

More venture news

Capsa AI
10 Jun 2026
Capsa AI lands £14m Series A led by TX Ventures and Pivot Investment Partners to build the AI operating system for private capital
Series AAI
NewOrbit
9 Jun 2026
NewOrbit raises £14m in a Series A led by Voyager Ventures to build the first commercial satellites for very low Earth orbit
Series ADeep Tech
IMU Biosciences
2 Jun 2026
IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
Series ALife Sciences

General Atlantic

Investment Portfolio

Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

More venture news

Capsa AI lands £14m Series A led by TX Ventures and Pivot Investment Partners to build the AI operating system for private capital

NewOrbit raises £14m in a Series A led by Voyager Ventures to build the first commercial satellites for very low Earth orbit

IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis